Medical Innovation Day is an annual event, which brings together students, researchers and business representatives to exchange ideas and think up solutions for health challenges of the future. In 2022, we will zoom in on post-marketing surveillance in connection with drug development under the theme: "What are the implications of post-marketing studies on innovation and future clinical trials?"
You can attend the event actively by joining one of two tracks; Challenge Track to take up a real-life case assignment or Innovative Ideas Track to test your own findings on a competent panel of investors, funds, venture capitals etc. You are also welcome to attend Medical Innovation Day simply as a guest/audience, and let yourself inspire by the pitches on innovative ideas and case solutions, and the exciting panel debate.
To round off the event, we invite you to join a career networking session.
Join one of two tracks to challenge yourself on innovative thinking:
There will be a prize for the winning team/presenter (to be announced).
We have invited panelists from several stakeholders, such as the Danish Medicines Agency and EU regulations, as well as actors representing the research and the pharmaceutical industry, and regional health politics, to discuss and put forward their different angles and opinions on the theme "What are the implications of post-marketing studies on innovation and future clinical trials?" in an exciting panel debate at Medical Innovation Day. We will introduce the panel debate with two short talks indicating the most important lessons for public health to be found in post-marketing studies of medicines - seen from a researcher's and an industry point of view. This will be followed up by a short talk from the authorities before ending the debate. Below is an introduction to the theme.
________________________________________
In 2013, The Organisation for Economic Cooperation and Development (OECD) stated 2013: “Health data constitutes a significant resource in most OECD countries, and it makes economic and ethical sense to use this data as much as possible: to improve population health and to improve the effectiveness, safety and patient-centeredness of health care systems.
Drug development involves rigorous evaluation of drugs on safety, tolerability, efficacy, and potential side effects in human subjects. In newly proposed phase 4 and 5 studies, any rare or long-term effects of the drug can be observed in a larger population of patients and over an extended period compared to earlier phases. If safety surveillance reveals concerns about the drug, it may be withdrawn from the market. The impact of this kind of post-marketing surveillance can be tremendous for both patient safety and pharma industry revenue.
One of the ways to do this is to perform phase 4* and phase 5** studies of medicine, medical devices, or treatments that is or has been introduced to the market. Typically, there is a need to look for rare side effects, interaction with other drugs, or a slide in the prescription within (some) medical groups.
In Denmark, we have access to various comprehensive sources of health data; socioeconomic factors, detailed disease-specific quality registries, and comprehensive use of electronic health records throughout the health care system. We also have clinical and population-based cohorts and an increasing number of large biobanks.
* Phase 4 studies: A type of clinical study that studies the side effects caused over time by a new treatment after it has been approved and is on the market. These studies look for side effects not seen in earlier clinical studies and may also study how well a new treatment works over a long period.
** Phase 5 studies: Commonly referred to as “post-marketing clinical studies.” Phase 5 study means a post-registrational Clinical Study conducted in any country or countries and not required as a condition to, or for the maintenance of, any Regulatory Approval for a Product in the Territory.
What does your future hold?
Meet the experts and get individual feedback on your innovation-related career options.
Come meet the panelists from Medical Innovation Day, other companies/organizations/ agencies, a founder in a start-up, and get your own individual feedback on your career options. Be inspired to get a better understanding of the skills and steps required to move into an innovation-related career path.
This career networking session at Medical Innovation Day will enable you as a student to discuss your preferred career with senior scientists, company representatives, organizations, agencies or a founder in a start-up. The experts in this session possess a broad range of professional backgrounds (biotech, science, innovation, administrative bodies and more) with the goal of inspiring students when choosing their unique career paths. The “Meet the experts” session will provide you with the opportunity to become more aware of and better informed about your career options available within Denmark.
Preparation
Upon registration, the students must book a seat with their preferred expert and upload a short CV which will be shared with the preferred expert.
We welcome cases and ideas with any relation to health in the broadest sense.
Be it directly related areas such as:
Or more indirectly related areas such as:
Medical Innovation Day is hosted by the Graduate School of Health (GSH) and its three doctoral programmes:
The event is arranged by a diverse organizing committee (see members in the right sidebar)
Main event:
27 Oct 2022
Venue: Aarhus University Hospital
Challenge track:
